Medical
Mohammad Reza Mohammadi; Amir Hossein Omidi; Hoda Sabati
Abstract
SARS-CoV- 2 is the causative agent of the global pandemic, also known as Covid-19. This virus belongs to a group of coronaviruses and has affected more than ten million people across the globe, causing nearly half a million deaths worldwide. The pandemic has spread worldwide, originating in the Wuhan ...
Read More
SARS-CoV- 2 is the causative agent of the global pandemic, also known as Covid-19. This virus belongs to a group of coronaviruses and has affected more than ten million people across the globe, causing nearly half a million deaths worldwide. The pandemic has spread worldwide, originating in the Wuhan Hubei province of China in 2019. The disease is a significant challenge as there is no antiviral treatment. This review will address current trends and emerging new methods for detecting SARS-CoV-2 in the laboratoryat present. Reverse transcriptase PCR or RT-PCR is the gold standard for detecting SARS-CoV-2 disease. The seroprevalence of Covid-19 is performed using antibody detection tests using ELISA and antigen detection as rapid tests. In clinical practice, preliminary disease identification is made based on Chest radiographs, computed tomography, and positron emission tomography (PET) scans. As the pandemic has progressed, newer methods of detection like CRISPR, nanotechnology-enabled solutions, and biosensors have emerged as new methods of detecting SARS-CoV-2.
Medical
Mohammad Reza Mohammadi; Hoda Sabati
Abstract
NCP (new coronavirus pneumonia) was discovered in Wuhan towards the end of 2019 and quickly spread throughout the city. The infection was identified as a novel coronavirus, and the World Health Organization (WHO) called it coronavirus disease-19 (COVID-19). Most people with this infection can experience ...
Read More
NCP (new coronavirus pneumonia) was discovered in Wuhan towards the end of 2019 and quickly spread throughout the city. The infection was identified as a novel coronavirus, and the World Health Organization (WHO) called it coronavirus disease-19 (COVID-19). Most people with this infection can experience mild to severe and even fatal symptoms after a period of disease incubation of 4 to 14 days. In up to 10% of patients, gastrointestinal symptoms such as nausea and diarrhea, as well as associated abdominal discomfort, may occur before respiratory symptoms. Several SARS-CoV-2 variations have been identified during the epidemic, however, only a handful are deemed variants of concern (VOCs) by the WHO due to their worldwide public health effect. In this article, we looked at new mutations in COVID-19 as well as the adverse effects of the virus on the cardiovascular and gastrointestinal tract. The discovery of these novel SARS-CoV-2 variations threatens to undo the substantial success made so far in restricting the spread of this viral disease, despite the extraordinary speed with which vaccines against COVID-19 have been developed and vigorous worldwide mass immunization efforts. Through mechanisms involving the dysregulated ACE 2 receptor and TMPRSS2, the SARS-CoV-2 virus has the potential to induce significant systemic disease in the GI tract, liver, biliary tract, and pancreas. Due to the observation of new and daily mutations of this dangerous virus, the definitive treatment of this disease is becoming more and more difficult and facing major challenges that it requires many clinical trials and researches.
)
)